[HTML][HTML] Duchenne muscular dystrophy: from diagnosis to therapy
MS Falzarano, C Scotton, C Passarelli, A Ferlini - Molecules, 2015 - mdpi.com
Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder due
to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and …
to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and …
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy
M Iftikhar, J Frey, MJ Shohan, S Malek… - Pharmacology & …, 2021 - Elsevier
Many neuromuscular diseases are genetically inherited or caused by mutations in motor
function proteins. Two of the most prevalent neuromuscular diseases are Duchenne …
function proteins. Two of the most prevalent neuromuscular diseases are Duchenne …
Intra‐arterial transplantation of HLA‐matched donor mesoangioblasts in Duchenne muscular dystrophy
G Cossu, SC Previtali, S Napolitano… - EMBO molecular …, 2015 - embopress.org
Intra‐arterial transplantation of mesoangioblasts proved safe and partially efficacious in
preclinical models of muscular dystrophy. We now report the first‐in‐human, exploratory …
preclinical models of muscular dystrophy. We now report the first‐in‐human, exploratory …
[HTML][HTML] Skeletal muscle fibrosis in the mdx/utrn+/-mouse validates its suitability as a murine model of Duchenne muscular dystrophy
KM Gutpell, WT Hrinivich, LM Hoffman - PloS one, 2015 - journals.plos.org
Various therapeutic approaches have been studied for the treatment of Duchenne muscular
dystrophy (DMD), but none of these approaches have led to significant long-term effects in …
dystrophy (DMD), but none of these approaches have led to significant long-term effects in …
Genome engineering: a new approach to gene therapy for neuromuscular disorders
CE Nelson, JN Robinson-Hamm… - Nature reviews …, 2017 - nature.com
For many neuromuscular disorders, including Duchenne muscular dystrophy, spinal
muscular atrophy and myotonic dystrophy, the genetic causes are well known. Gene therapy …
muscular atrophy and myotonic dystrophy, the genetic causes are well known. Gene therapy …
Duchenne muscular dystrophy: an updated review of common available therapies
Background and purpose: Duchenne muscular dystrophy (DMD) is a lethal progressive
pediatric muscle disorder and genetically inherited as an X-linked disease that caused by …
pediatric muscle disorder and genetically inherited as an X-linked disease that caused by …
[HTML][HTML] Current translational research and murine models for Duchenne muscular dystrophy
M Rodrigues, Y Echigoya, S Fukada… - Journal of …, 2016 - content.iospress.com
Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder characterized by
progressive muscle degeneration. Mutations in the DMD gene result in the absence of …
progressive muscle degeneration. Mutations in the DMD gene result in the absence of …
Perspective on adeno-associated virus capsid modification for Duchenne muscular dystrophy gene therapy
ME Nance, D Duan - Human gene therapy, 2015 - liebertpub.com
Duchenne muscular dystrophy (DMD) is a X-linked, progressive childhood myopathy
caused by mutations in the dystrophin gene, one of the largest genes in the genome. It is …
caused by mutations in the dystrophin gene, one of the largest genes in the genome. It is …
[HTML][HTML] Quantifying disease activity in fatty-infiltrated skeletal muscle by IDEAL-CPMG in Duchenne muscular dystrophy
A Mankodi, CA Bishop, S Auh, RD Newbould… - Neuromuscular …, 2016 - Elsevier
The purpose of this study was to explore the use of iterative decomposition of water and fat
with echo asymmetry and least-squares estimation Carr–Purcell–Meiboom–Gill (IDEAL …
with echo asymmetry and least-squares estimation Carr–Purcell–Meiboom–Gill (IDEAL …
Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders
HL Peay, BB Biesecker, BS Wilfond, J Jarecki… - Clinical …, 2018 - journals.sagepub.com
Background/aims: Pediatric rare disease presents a challenging situation of high unmet
need and a limited pool of potential clinical trial participants. Understanding perspectives of …
need and a limited pool of potential clinical trial participants. Understanding perspectives of …